Molecularly Targeted Therapy for Neuroblastoma
AbstractNeuroblastoma is the most common extra-cranial solid tumor encountered in childhood and accounts for 15% of pediatric cancer-related deaths. Although there has been significant improvement in the outcomes for patients with high-risk disease, the therapy needed to achieve a cure is quite toxic and for those that do experience a disease recurrence, the prognosis is very dismal. Given this, there is a tremendous need for novel therapies for children with high-risk neuroblastoma and the molecular discoveries over recent years provide hope for developing new, less toxic, and potentially more efficacious treatments. Here I discuss many of the molecular aberrations identified thus far in neuroblastoma, as well as the agents in development to target these changes. The progress made in both the preclinical arena and in early phase drug development provide much promise for the future of precision medicine in neuroblastoma. View Full-Text
Share & Cite This Article
Greengard, E.G. Molecularly Targeted Therapy for Neuroblastoma. Children 2018, 5, 142.
Greengard EG. Molecularly Targeted Therapy for Neuroblastoma. Children. 2018; 5(10):142.Chicago/Turabian Style
Greengard, Emily G. 2018. "Molecularly Targeted Therapy for Neuroblastoma." Children 5, no. 10: 142.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.